Key facts
- This page summarizes Mark Allen Bach's Form 4 filing for Structure Therapeutics Inc. (GPCR).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 19 Mar 2024, 16:46.
Mark Allen Bach - 15 Mar 2024 Form 4 Insider Report for Structure Therapeutics Inc. (GPCR)
- Reporting relationship
- CHIEF MEDICAL OFFICER
- Issuer ticker
- GPCR
- Reported as of
- 15 Mar 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 19 Mar 2024, 16:46:29 UTC
- Prior SEC filing
- 09 Feb 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jun Yoon, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Mark Allen Bach filed Form 4 for Structure Therapeutics Inc. (GPCR) on 19 Mar 2024.
Change
- Previous filing in this sequence was filed on 09 Feb 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
GPCR
transaction
Ordinary Shares
Award
- Transaction value
- $0
- Shares
- +26,235
- Change %
- Price
- $0.000000
- Shares after
- 26,235
- Date
- 15 Mar 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
GPCR
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +65,352
- Change %
- Price
- $0.000000
- Shares after
- 65,352
- Date
- 15 Mar 2024
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 65,352
- Exercise price
- $35.25
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one ordinary share of the Issuer. The RSUs vest 1/4th annually on each anniversary of March 1, 2024, subject to Reporting Person's continued service on such dates.
Footnote F2
1/4th of the shares subject to the option shall vest March 1, 2025, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each such vesting date.